Navigation Links
Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance
Date:9/3/2014

s at the date of this release. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie is set forth in Item 1A, "Risk Factors," in AbbVie's 2013 Annual Report on Form 10-K and in Item 1A, "Risk Factors" of Part II of AbbVie's second quarter 2014 Quarterly Report on Form 10-Q, which have been filed with the SEC, the contents of which are not incorporated by reference into, nor do they form part of, this release. Neither AbbVie nor Shire undertakes any obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Schedule 1
Profit Forecasts for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014

In accordance with Rule 28.4(a) of the Code, the principal assumptions upon which the profit forecasts are based are included in this Schedule 1 to the announcement. In accordance with Rule 28.4(b) of the Code, there is a clear distinction made between assumptions which the Directors of AbbVie (or other members of AbbVie's management) can influence and those which they cannot influence.

1.            General

AbbVie is amending its GAAP earnings guidance for the year ending December 31, 2014 and the third quarter ending September 30, 2014 as follows:

Revised Full-Year 2014 GAAP guidance:

Excluding the potential impact of the transaction with Shire, AbbVie is reducing its full year 2014 earnings-per-share guidance range on a GAAP basis to $2.11 to $2.21 after reflecting a reduction of $0.47 per share in relation to the upfront investment as part of the collaboration agreement with Calico and a reduction of $0.11 per share in relation to the upfront investment in the Infinity collaboration.  The full amount of both investments will be treated as a specified expens
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
2. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
3. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
4. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
5. WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
6. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
7. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
8. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
9. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
10. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
11. Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Seahorse Bioscience, ... metabolism, is the provider of XF Technology which ... disease research areas. As the links between mitochondrial ... cell metabolism is escalating rapidly.   ... the Nature Publishing Group (NPG) featuring XF Technology, ...
(Date:7/28/2015)... , July 28, 2015 Deerfield Management ... Healthcare Innovations Fund, L.P., which will invest in groundbreaking ... in genetic diseases, cancer, and orphan diseases. The venture ... transform how therapeutics are developed and improve the way ... one of the largest healthcare-focused venture funds in the ...
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
(Date:7/27/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... on Thursday, July 30, 2015, after the close of ... by a conference call with the investment community at ... will be Robert A. Bradway , chairman and ... management team. Live audio of the conference ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... 29, 2011 Today BioSpace , the leading ... Biotech Beach™ Hotbed Campaign, marking the 14th edition. ... organizations across Southern California. Each company,s brand is added ... that is promoted online as well as at industry ...
... 29, 2011 Children,s Oncology Group (COG) ... will jointly investigate Apeiron,s APN301 in a clinical phase ... Biologics AG (Apeiron) and the Children,s Oncology Group (COG) ... II study in neuroblastoma patients. Neuroblastoma, a cancer of ...
... Omer Bayrak made headlines when he became the first ... using the Freedom® portable driver to power his SynCardia temporary ... matching donor heart, Mr. Bayrak has been enjoying his new-found ... a heart." (Photo: http://photos.prnewswire.com/prnh/20110929/LA77026-a ) ...
Cached Biology Technology:BioSpace Spotlights Southern California's Life Science Community 2Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301) 2Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301) 3Children's Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301) 4Total Artificial Heart Patient Enjoys Spotlight as "The Only Man in Turkey Who Lives Without a Heart" 2Total Artificial Heart Patient Enjoys Spotlight as "The Only Man in Turkey Who Lives Without a Heart" 3
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... , July 8, 2015 The consumer ... this summer,s must have products such as wearables, smart wallets ... popularity for biometrics based devices continues to rapidly grow.  Biometrics ... (NASDAQ: NXTD ), Google Inc. (NASDAQ: GOOG ), ... FIT ), GoPro, Inc. (NASDAQ: GPRO ) and Baidu ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... New York University biologists have uncovered how the innate ... neurons. The findings, published as the cover study in ... neurons fight the virus at multiple stages--by preventing the ... virus' release, which could infect other cells in the ...
... infect multiple species within a community and are ... associated with pathogen emergence and therefore has been ... and species of agricultural importance. Many pathogens like ... infect multiple hosts are commonly transmitted by vectors, ...
... complete bacterial genome sequence was published. Now, nearly 200 ... hits the scientific press most weeks. This burgeoning industry ... genome sequences may provide useful clues about why some ... and how to treat the infections caused by them. ...
Cached Biology News:NYU study reveals how brain's immune system fights viral encephalitis 2A new study examines how shared pathogens affect host populations 2Multiple Campylobacter Genomes Sequenced 2
... This exceptionally sensitive nucleic acid gel stain has ... background in gels, making it ideal for detecting ... UV transilluminators. SYBR Green I nucleic acid ... electrophoresis, real-time PCR assays and bandshift assays. ...
... 1) Persistent Analysis Environment 2) Dot ... etc. 3) Software Compensation 4) Cell ... Kinetics Platform 7) Intelligent batch generation of ... smoothing 9) Single drag-and-drop operations to perform ...
Synonym: modified Grace's Insect medium...
Eagle's Ham's amino acids; EHAA...
Biology Products: